Topics

EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe

09:14 EST 31 Jan 2020 | Medscape

The CHMP has recommended approval of bempedoic acid (Nilemdo) and the combination of bempedoic acid/ezetimibe (Nustendi) for primary hypercholesterolemia and mixed dyslipidemia.
International Approvals

Original Article: EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe

NEXT ARTICLE

More From BioPortfolio on "EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe"

Quick Search